TYK-00540 tablets for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a new tablet, TYK-00540, alone or with another drug, for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must be advanced or metastatic and standard treatments no longer work, are not tolerated, or are refused.
- You need to have tumors that can be measured on scans or evaluated by a doctor.
- You must be well enough to perform daily activities (ECOG score 0 or 1).
- Your organ functions (liver, kidneys, heart, blood) must be within certain limits.
- For some study groups, you may need to have a specific type of cancer, such as ovarian or breast cancer, with certain treatment history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called TYK-01054 for people with advanced solid tumors that have stopped responding to standard treatment. The drug targets a specific cell pathway (Hippo) that may help slow or stop tumor growth.
This trial tests a new drug called HSK39775 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective for people who have few other options.
This trial tests a new drug called HSK46256 for people with advanced solid tumors that have not responded to standard treatments. The drug may target cancer cells with certain genetic changes, and the study aims to find the best dose and see how well it works.
This trial tests a new combination of two study drugs (GH55 and GH21) for people with advanced solid tumors that have certain genetic changes. The goal is to see if the combo is safe and can help shrink tumors or slow their growth.
This trial tests a new combination treatment for people with advanced solid tumors that have not responded to standard therapy. It aims to find a safe dose and see if the combination can shrink tumors.
This trial tests a new drug, TYK-00540, for people with solid tumors that have not responded to or cannot tolerate standard treatments. It also looks at specific types of breast and ovarian cancer.
Hear when a new HR-positive, HER2-negative Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.